These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 25155937)
1. Should we keep on? Looking into pharmacogenomics of ADHD in adulthood from a different perspective. Rovaris DL; Mota NR; da Silva BS; Girardi P; Victor MM; Grevet EH; Bau CH; Contini V Pharmacogenomics; 2014 Jul; 15(10):1365-81. PubMed ID: 25155937 [TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of response to methylphenidate in adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review. Contini V; Rovaris DL; Victor MM; Grevet EH; Rohde LA; Bau CH Eur Neuropsychopharmacol; 2013 Jun; 23(6):555-60. PubMed ID: 22709890 [TBL] [Abstract][Full Text] [Related]
3. Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics. Polanczyk G; Zeni C; Genro JP; Roman T; Hutz MH; Rohde LA Pharmacogenomics; 2005 Apr; 6(3):225-34. PubMed ID: 16013954 [TBL] [Abstract][Full Text] [Related]
4. Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies. Bonvicini C; Faraone SV; Scassellati C Mol Psychiatry; 2016 Jul; 21(7):872-84. PubMed ID: 27217152 [TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. Kambeitz J; Romanos M; Ettinger U Pharmacogenomics J; 2014 Feb; 14(1):77-84. PubMed ID: 23588108 [TBL] [Abstract][Full Text] [Related]
7. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Polanczyk G; Zeni C; Genro JP; GuimarĂ£es AP; Roman T; Hutz MH; Rohde LA Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289 [TBL] [Abstract][Full Text] [Related]
8. A current update on ADHD pharmacogenomics. Kieling C; Genro JP; Hutz MH; Rohde LA Pharmacogenomics; 2010 Mar; 11(3):407-19. PubMed ID: 20235795 [TBL] [Abstract][Full Text] [Related]
9. Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder. Bellgrove MA; Hawi Z; Kirley A; Fitzgerald M; Gill M; Robertson IH Neuropsychopharmacology; 2005 Dec; 30(12):2290-7. PubMed ID: 16123773 [TBL] [Abstract][Full Text] [Related]
10. No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD. Contini V; Victor MM; Bertuzzi GP; Salgado CA; Picon FA; Grevet EH; Rohde LA; Belmonte-de-Abreu P; Bau CH J Clin Psychopharmacol; 2012 Dec; 32(6):820-3. PubMed ID: 23131881 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: association with the dopamine transporter gene (SLC6A3). Purper-Ouakil D; Wohl M; Orejarena S; Cortese S; Boni C; Asch M; Mouren MC; Gorwood P Am J Med Genet B Neuropsychiatr Genet; 2008 Dec; 147B(8):1425-30. PubMed ID: 18563707 [TBL] [Abstract][Full Text] [Related]
12. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Sharma A; Couture J Ann Pharmacother; 2014 Feb; 48(2):209-25. PubMed ID: 24259638 [TBL] [Abstract][Full Text] [Related]
13. Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder. Kim BN; Kim JW; Cummins TD; Bellgrove MA; Hawi Z; Hong SB; Yang YH; Kim HJ; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH J Clin Psychopharmacol; 2013 Jun; 33(3):356-62. PubMed ID: 23609393 [TBL] [Abstract][Full Text] [Related]
14. Dopamine transporter 3'-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate. Joober R; Grizenko N; Sengupta S; Amor LB; Schmitz N; Schwartz G; Karama S; Lageix P; Fathalli F; Torkaman-Zehi A; Ter Stepanian M Neuropsychopharmacology; 2007 Jun; 32(6):1370-6. PubMed ID: 17063150 [TBL] [Abstract][Full Text] [Related]
15. Attention deficit and hyperactivity disorder: review of genetic association studies. Galili-Weisstub E; Segman RH Isr J Psychiatry Relat Sci; 2003; 40(1):57-66. PubMed ID: 12817670 [TBL] [Abstract][Full Text] [Related]
16. Neuroimaging markers for the prediction of treatment response to Methylphenidate in ADHD. Skokauskas N; Hitoshi K; Shuji H; Frodl T Eur J Paediatr Neurol; 2013 Nov; 17(6):543-51. PubMed ID: 23672833 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of methylphenidate response: making progress. Mrazek DA J Am Acad Child Adolesc Psychiatry; 2009 Dec; 48(12):1140-2. PubMed ID: 20854782 [No Abstract] [Full Text] [Related]
18. Neurocognitive effects of methylphenidate on ADHD children with different DAT genotypes: a longitudinal open label trial. Pasini A; Sinibaldi L; Paloscia C; Douzgou S; Pitzianti MB; Romeo E; Curatolo P; Pizzuti A Eur J Paediatr Neurol; 2013 Jul; 17(4):407-14. PubMed ID: 23541676 [TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)]. Golubchik P; Sever J; Weizman A Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124 [TBL] [Abstract][Full Text] [Related]